Table 1
Characteristics of Patients

Clinical Characteristics	Followed Patients (%)	Not Followed Patients (%)	P-value
Total patients	238 (100)	21 (100)	—
Age (mean ± SD), years	59.1 ± 11.6	57.1 ± 14.0	0.14
Sex	—	—	0.36
Male	107 (45.0)	12 (57.1)	—
Female	131 (55.0)	9 (42.9)	—
Subtype of adjustment disorders	—	—	0.62
Mixed anxiety and depressed mood	97 (40.8)	8 (38.1)	—
With anxiety	76 (31.9)	5 (23.8)	—
With depressed mood	60 (25.2)	7 (33.3)	—
Mixed disturbance of emotions and conduct	2 (0.8)	0 (0)	—
Unspecified	3 (1.3)	1 (4.8)	—
Primary cancer site	—	—	0.55
Lung	49 (20.6)	5 (23.8)	—
Head and neck	38 (16.0)	4 (19.0)	—
Breast	35 (14.7)	2 (9.5)	—
Colon	24 (10.1)	5 (23.8)	—
Esophageal	21 (8.8)	1 (4.8)	—
Stomach	17 (7.1)	1 (4.8)	—
Others	54 (22.7)	3 (14.3)	—
Clinical tumor stage	—	—	0.10
Stage I–III	89 (37.4)	4 (19.0)	—
Stage IV or recurrent	149 (62.6)	17 (81.0)	—
Performance status (ECOG)[a]	—	—	0.01
0	81 (34.0)	1 (4.8)	—
1	79 (33.2)	8 (38.1)	—
2–4	78 (32.8)	12 (57.1)	—
Pain	—	—	0.03
Absent or little (0–1)	153 (64.3)	8 (38.1)	—
Tolerable or intolerable (2–3)	85 (35.7)	13 (61.9)	—
Married	—	—	0.49
Yes	189 (79.4)	18 (85.7)	—
No	49 (20.6)	3 (14.3)	—
Employment	—	—	0.30
Employed	86 (36.1)	10 (47.6)	—
Not employed	152 (63.9)	11 (52.4)	—

SD = standard deviation.
[a]Performance status as defined by the Eastern Cooperative Oncology Group.

Together with our results, these findings suggest that medically ill patients with AD tend to recover after psychiatric intervention.

Several studies have assessed the clinical course of AD. Andreasen et al.[26] indicated that 75.3% of adult patients tend to recover from AD within six months but that 43% of adolescent patients with AD developed a major psychiatric disorder, such as schizophrenia, major depression, substance abuse, or a personality disorder. In a follow-up study of cancer patients with AD treated in a palliative care setting for two months, 41.7% of the patients recovered from their mental illnesses, but the remaining patients continued to exhibit symptoms of AD.[7] For advanced lung cancer patients with AD, 53.8% of the patients had

recovered at a six-month follow-up, but the other patients continued to exhibit the symptoms of AD.[5] As these findings suggest, some patients with AD are curable without intervention, and a certain percentage of our subjects may have recovered spontaneously.

On the other hand, 2.9% of the patients developed major depressive disorders. A previous study showed that 21% of adults with AD had developed a major depressive disorder or alcoholism at the time of a five-year follow-up examination,[26] and 41.7% of cancer patients in a palliative care setting had developed a major depressive disorder at a two-month follow-up.[7] These results cannot be compared with the present results, as the follow-up periods of the two studies were different. It is

Table 2
Predictive Factors for Treatment Response of ADs—Logistic Regression Analysis

Predictive Factors	Responded Case (%)	Others (%)	OR (95%CI)	*P*-value
Total patients	136 (100)	102 (100)	—	—
Age (mean ± SD), years	60.0 ± 12.0	58.0 ± 11.1	0.99 (0.96–1.01)	0.25
Sex				
Male	60 (44.1)	47 (46.1)	—	—
Female	76 (55.9)	55 (53.9)	0.91 (0.50–1.63)	0.74
Clinical tumor stage				
Stage I–III	48 (35.3)	41 (40.2)	—	—
Stage IV or recurrent	88 (64.7)	61 (59.8)	0.82 (0.46–1.47)	0.51
Performance status (ECOG)[a]				
0	50 (36.7)	31 (30.4)	—	—
1	45 (33.1)	34 (33.3)	1.41 (0.72–2.76)	0.31
2–4	41 (30.1)	37 (36.3)	2.27 (1.09–4.74)	0.03
Pain				
Absent or little (0–1)	82 (60.3)	71 (69.6)	—	—
Tolerable or intolerable (2–3)	54 (39.7)	31 (30.4)	0.52 (0.28–0.99)	0.05
Married				
Yes	110 (80.9)	79 (77.5)	—	—
No	26 (19.1)	23 (22.5)	1.36 (0.70–2.65)	0.36
Employment				
Employed	46 (33.8)	40 (39.2)	—	—
Not employed	90 (66.2)	62 (60.8)	0.91 (0.49–1.71)	0.78

SD = standard deviation; OR = odds ratio; CI = confidence interval.
[a]Performance status as defined by the Eastern Cooperative Oncology Group.

not clear whether our comparably low rate of major depression was because of the effectiveness of treatment or if more patients might have developed major depression after a longer observation period. Further studies of AD in cancer patients treated with psychiatric intervention with longer follow-up periods are needed to clarify this point.

We explored the demographic and physical factors that predicted a response to treatment. Suffering from pain predicted a favorable treatment response, and a performance status worse than 2 predicted a poor treatment response, compared with a performance status of 0. No other studies have shed light on predictors of treatment response, and these results provide valuable information for physicians. Pain is a strong stressor and has been associated with AD or major depressive disorders in previous studies;[5,27,28] consequently, this result seems paradoxical because patients who were suffering from pain at baseline responded to treatment more often than patients who were not suffering from pain, with an odds ratio of 0.52 (95% confidence interval, 0.28–0.99). Although the mechanism responsible for this result is unclear, we speculate that this pain might have been alleviated

during the follow-up period, contributing to the better outcome. As we lack follow-up data on pain to test this speculation, further study examining the clinical courses of both pain and ADs is needed.

A poor performance status also has been shown to be strongly associated with AD,[7,29] and our results showed that a poor performance status predicted a poor treatment response. A poor performance status can elicit persistent psychological distress and may hinder remission from AD because the performance status of cancer patients usually deteriorates continuously and rarely improves,[30,31] unlike the pain experienced by cancer patients.

The present study had several limitations. First, this study was based on a consultation case basis, and the actual incidence of AD might have been much greater if every patient in the ward had been screened. Furthermore, a patient selection bias may exist because the subjects of this study comprised preselected patients who may have had more obvious conditions or may have been more willing to see a psychiatrist. Second, this study was held in a single cancer center, and we should consider institutional bias because of physician influence and other factors. Third, there is

a possibility of assessment bias. Although we made the clinical diagnoses according to DSM-IV criteria and the psychiatric diagnoses were confirmed at a weekly meeting of the psychiatry department, it is a less robust method than a structured diagnostic interview. Also, the CGI is a subjective scale and does not have a specific anchor point. Fourth, the predictors of treatment response that were explored in this study were limited to those that could be extracted from the patients' medical charts, and some important factors, such as educational status,[3] were not included. Fifth, no information was presented with respect to two medical issues: the time since diagnosis and how many patients were receiving medical treatment. Both of these factors may have affected distress levels and the speed of spontaneous recovery.

Although our study has several limitations, some highly suggestive results emerged as helpful information for clinical practice and for suggesting future studies. To elucidate the entire picture of treatment response for AD in cancer patients, further research addressing the present study's limitations is needed.

Disclosures and Acknowledgments

References

1. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983;249:751−757.

2. Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer 1996; 78:1131−1137.

3. Kugaya A, Akechi T, Okamura H, Mikami I, Uchitomi Y. Correlates of depressed mood in

4. Okamura H, Watanabe T, Narabayashi M, et al. Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors. Breast Cancer Res Treat 2000;61: 131−137.

5. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma: a longitudinal study. Cancer 2001; 92:2609−2622.

6. Uchitomi Y, Mikami I, Nagai K, et al. Depression and psychological distress in patients during the year after curative resection of non-small-cell lung cancer. J Clin Oncol 2003;21:69−77.

7. Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004;22:1957−1965.

8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.

9. Strain JJ, Diefenbacher A. The adjustment disorders: the conundrums of the diagnoses. Compr Psychiatry 2008;49:121−130.

10. Akechi T, Kugaya A, Okamura H, et al. Suicidal thoughts in cancer patients: clinical experience in psycho-oncology. Psychiatry Clin Neurosci 1999;53: 569−573.

11. Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer 2002;95: 1085−1093.

12. Grassi L, Indelli M, Marzola M, et al. Depressive symptoms and quality of life in home-care-assisted cancer patients. J Pain Symptom Manage 1996;12: 300−307.

13. Prieto JM, Blanch J, Atala J, et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol 2002;20: 1907−1917.

14. Cassileth BR, Lusk EJ, Strouse TB, et al. A psychological analysis of cancer patients and their next-of-kin. Cancer 1985;55:72−76.

15. Strain JJ, Smith GC, Hammer JS, et al. Adjustment disorder: a multisite study of its utilization and interventions in the consultation-liaison psychiatry setting. Gen Hosp Psychiatry 1998;20:139−149.

16. Kishi Y, Meller WH, Kato M, et al. A comparison of psychiatric consultation liaison services between hospitals in the United States and Japan. Psychosomatics 2007;48:517−522.

17. Akechi T, Nakano T, Okamura H, et al. Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. Jpn J Clin Oncol 2001;31:188—194.

18. Razavi D, Kormoss N, Collard A, Farvacques C, Delvaux N. Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. J Int Med Res 1999;27:264—272.

19. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand 1996;94: 205—210.

20. Akechi T, Suzuki S, Taniguchi K, et al. State of the art of psychotherapy for anxiety and depression among patients with advanced or terminally ill cancer—systematic review. Jpn J Psychiatr Treat 2003;18:571—577.

21. Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991;9:1004—1011.

22. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.

23. Riedel M, Moller HJ, Obermeier M, et al. Response and remission criteria in major depression—

a validation of current practice. J Psychiatr Res 2010; 44:1063—1068.

24. Chen AM, Jennelle RL, Grady V, et al. Prospective study of psychosocial distress among patients undergoing radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2009;73:187—193.

25. Snyder S, Strain JJ. Change in diagnosis at termination of psychiatric consultation. Hosp Community Psychiatry 1990;41:286—289.

26. Andreasen NC, Hoenk PR. The predictive value of adjustment disorders: a follow-up study. Am J Psychiatry 1982;139:584—590.

27. Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994;74: 2570—2578.

28. Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry 1995;152:1185—1191.

29. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. J Clin Oncol 2000;18:893—903.

30. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA 2003;289:2387—2392.

31. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ 2005;330: 1007—1011.

Case Report

Coexistence of TDP-43 and tau pathology in neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome)

Takashi Haraguchi,[1] Seishi Terada,[2] Hideki Ishizu,[3] Osamu Yokota,[2] Hidenori Yoshida,[1]
Naoya Takeda,[2] Yuki Kishimoto,[2] Naoko Katayama,[1] Hiroshi Takata,[4] Motohiro Akagi,[5]
Shigetoshi Kuroda,[3] Yuetsu Ihara[1] and Yosuke Uchitomi[2]

[1]Department of Neurology, National Hospital Organization Minami-Okayama Medical Center, [2]Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, [3]Department of Laboratory and Medicine, Zikei Institute, Okayama, [4]Department of Neurology, Kinashi Obayashi Hospital, Takamatsu and [5]Department of Developmental Medicine (Pediatrics), Osaka University Graduate School of Medicine, Osaka, Japan

We report here an autopsy case of sporadic adult-onset Hallervorden-Spatz syndrome, also known as neurodegeneration with brain iron accumulation type 1 (NBIA1), without hereditary burden. A 49-year-old woman died after a 27-year disease course. At the age of 22, she suffered from akinesia, resting tremor, and rigidity. At the age of 28, she was admitted to our hospital because of worsening parkinsonism and dementia. Within several years, she developed akinetic mutism. At the age of 49, she died of bleeding from a tracheostomy. Autopsy revealed a severely atrophic brain weighing 460 g. Histologically, there were iron deposits in the globus pallidus and substantia nigra pars reticulata, and numerous axonal spheroids in the subthalamic nuclei. Neurofibrillary tangles were abundant in the hippocampus, cerebral neocortex, basal ganglia, and brain stem. Neuritic plaques and amyloid deposits were absent. Lewy bodies and Lewy neurites, which are immunolabeled by anti-α-synuclein, were absent. We also observed the presence of TDP-43-positive neuronal perinuclear cytoplasmic inclusions, with variable frequency in the dentate gyrus granular cells, frontal and temporal cortices, and basal ganglia. TDP-43-positive glial cytoplasmic inclusions were also found

with variable frequency in the frontal and temporal lobes and basal ganglia. The present case was diagnosed with adult-onset NBIA-1 with typical histological findings in the basal ganglia and brainstem. However, in this case, tau and TDP-43 pathology was exceedingly more abundant than α-synuclein pathology. This case contributes to the increasing evidence for the heterogeneity of NBIA-1.

INTRODUCTION

Hallervorden-Spatz syndrome (HSS) is an autosomal recessive[1] or sporadically occurring neurodegenerative disorder characterized clinically by rigidity and/or spasticity in the limbs, extrapyramidal movement disorders, and mental deterioration.[2] Due to historical discussions, the syndrome was renamed "neurodegeneration with brain iron accumulation type 1" (NBIA-1),[3] and due to recent molecular genetic findings, it has been classed as a pantothenase kinase-associated neurodegeneration (PKAN).[4,5] The known mutations are detected in around 25% of NBIA-1 patients. Neuropathological changes are characterized by iron accumulation, variable neuronal loss and gliosis, and axonal spheroids, mainly affecting the globus pallidus and substantia nigra.[6] Besides the axonal spheroids and iron accumulation, other neuropathological lesions have been

reported in NBIA-1. Lewy bodies were first observed with routine staining[6-9] and later confirmed with modern immunohistochemical methods.[3,10-15] These observations led to the suggestion that NBIA-1 should be included among the α-synucleinopathies with Parkinson's disease, multiple-system atrophy, and Lewy body dementia.[16] Similarly, neurofibrillary tangles (NFTs) in NBIA-1 brains were first visualized using the classic argentic methods[9,17-23] and more recently confirmed with immunohistochemistry for hyperphosphorylated tau protein.[11,13-15,24,25] In several cases, both α-synuclein and tau pathology coexisted.[9,11-15,19,24,25] Thus, it has been debated whether this disease should be classified as an α-synucleinopathy.

TAR-DNA-binding protein 43 (TDP-43) has recently been identified as a major disease protein in the ubiquitinated inclusions in frontotemporal lobar degeneration (FTLD) with ubiquitin-positive and tau-negative inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS).[26] However, subsequent studies have detected TDP-43-positive inclusions in other neurodegenerative disorders, including Parkinson's disease and dementia with Lewy bodies (DLB),[27] parkinsonism–dementia complex (PDC) and ALS in Guam,[28,29] corticobasal degeneration (CBD),[30] and Alzheimer's disease (AD).[30,31]

Here we report the clinical, pathological, and genetic findings of a patient with NBIA-1 whose postmortem examination revealed neuroaxonal dystrophy with widespread NFTs and TDP-43-positive inclusions. We also review the previously reported cases of NBIA-1 accompanied by tau and/or α-synuclein pathology.

CASE REPORT

Clinical course

The patient was a Japanese woman who was 49 years old at the time of death. She had neither a family history of neurological disease nor dementing disorder anamnesis. The patient was normal at birth and attended school until the age of 15; her school performance was unsatisfactory. She developed akinesia, resting tremor, and rigidospastic gait at the age of 22. Over the next 6 years, her gait disturbance and limb rigidity progressed very slowly. Neurological examination at age 22 showed an akinetic gait, rigidity and hyper-reflexia of the upper and lower extremities, pathological reflexes, slow eye movement, childish speech, and mental deterioration. There were no sensory abnormalities or cerebellar signs. The patient became unable to walk at the age of 24. Dopaminergic treatment was ineffective. Thereafter, dementia, dysphasia, spastic tetraparesis, and gaze limitation progressed rapidly. She developed myoclonic jerks of her upper extremities at age 32. The myoclonus increased in frequency and spread to involve the lower extremities. A generalized convulsion occurred at the age of 33. Anti-convulsive treatment was initiated and was effective. She progressed to a rigid vegetative state with incontinence at age 33, and by age 35, she was mute and immobile. Numerous investigations were done including examinations of the eye, bone marrow, serum corticosteroids, α- and β-glucosidase, α- and β-galactosidase, α-mannosidase, α-fucosidase, β-glucuronidase, N-acetyl β-glucosaminidase, hexosaminidase A, arylsulfatase A, copper and iron, ceruloplasmin, amino acids, anti-mitochondrial antibody, and vitamin B_{12} levels, all of which were within normal limits. Cerebrospinal fluid revealed normal protein, IgG, glucose, and cell count. Electroencephalograms showed irregular 8- to 9-Hz α-waves mixed with 5- to 7-Hz θ-waves. At age 34, head MRI showed a slight decrease in signal intensity in the globus pallidus and substantia nigra, and severe atrophy of the frontal, temporal lobes, cerebellum, and brainstem (Fig. 1). Although the patient presented with progressive parkinsonism and dementia, we could not establish a definite clinical diagnosis because no biochemical and radiological findings confirmed one. At the age of 49, she


Fig. 1 Cranial MRI (axial, T2-weighted image), showing a slight decrease in signal intensity in the globus pallidus and substantia nigra and severe atrophy of the frontal, temporal lobes, and brainstem. (R, right side).

died of bleeding from a tracheostomy. The autopsy was limited to the brain.

Neuropathological findings

The fixed brain weighed 460 g. Macroscopic examination revealed generalized gyral atrophy in both cerebral hemispheres, especially in the frontal and temporal lobes (Fig. 2a). Serial coronal sections of the brain showed severe cortical atrophy involving the orbital and cingulate gyri (Fig. 2b) as well as the medial temporal lobe, including the amygdala and hippocampus (Fig. 2c). The caudate nuclei were severely atrophied, and there was marked dilatation of the lateral ventricles. Additionally, the globus pallidus was light brown and atrophied (Fig. 2c). Serial axial sections of the brain stem showed brown discoloration of the substantia nigra and locus coeruleus. Serial

Fig. 2 External lateral view, coronal sections of the right hemisphere. (a) Cerebrum after stripping of the leptomeninges showing "knife-edge" atrophy of the frontal and temporal lobes. (b) Prominent atrophy of orbital surface of the frontal lobe and cingulate gyri. (c) Severe atrophy of the cingulate gyri, insula, amygdala, and temporal lobe. Mild pigmentation of the inner segment of the globus pallidus (arrow).

© 2011 Japanese Society of Neuropathology

sagittal sections of the cerebellum revealed severe cortical atrophy as well as brown discoloration and atrophy of the dentate nuclei. Meninges and blood vessels were normal.

The brain was fixed in 10% buffered formalin. Multiple paraffin-embedded tissue blocks were prepared, and 6-μm-thick sections were cut. These sections were stained with HE, KB, Bodian, Berlin blue, and Gallyas-Braak methods.

The following primary antibodies and dilutions were used for immunology studies: anti-phosphorylated tau (AT8; mouse monoclonal; 1:1000; Innogenetics, Ghent, Belgium), anti-phosphorylated α-synuclein (pSyn#64; mouse monoclonal; 1:5000; Wako, Osaka, Japan), anti-phosphorylated TDP-43 (pS409/410-2; rabbit polyclonal; 1:5000; Cosmo Bio, Tokyo, Japan).

Microscopic examination showed brown-pigmented, iron-positive granules around the blood vessels and throughout the neuropil in the globus pallidus (Fig. 3a) and the pars reticulata of the substantia nigra. In addition, numerous axonal spheroids were observed predominantly in the subthalamic (Fig. 3b) and dentate nuclei, globus pallidus, substantia nigra pars reticulate, and cerebellar cortex. Marked neuronal loss and gliosis were most pronounced in the frontal (Fig. 3c) and temporal cortices. In the most affected regions microvacuolar changes were seen within the outer cortical laminae. Marked gliosis was found in the frontal (Fig. 3d) and temporal white matter. Severe loss of neurons with gliosis was also found in the globus pallidus and neostriatum. The substantia nigra pars compacta was characterized by marked neuronal depletion, and the remaining cells had a low melanin content (Fig. 3e). In the medulla oblongata the cuneate and gracile nuclei were severely affected, showing neuronal loss and gliosis. A moderate depletion of Purkinje cells and proliferation of Bergmann astrocytes was noted in the cerebellum (Fig. 3f). In the dentate nucleus there was moderate neuronal cell loss, as well as several axonal spheroids. In addition to these changes, many NFTs and neuropil threads were found in the cerebral neocortex (Fig. 3g), hippocampus, basal ganglia, thalamus, substantia nigra and reticular formation of the brain stem. These NFTs and threads reacted strongly with anti-phosphorylation-dependent tau protein (Fig. 3h). Immunohistochemistry for α-synuclein enabled the detection of numerous foamy spheroids in the substantia nigra (Fig. 3i). Approximately 90% of foamy spheroids were positive for α-synuclein. However, no LBs or Lewy neurites were observed. The axonal spheroids in the subthalamic nuclei and globus pallidus were consistently negative for α-synuclein and tau. TDP-43-positive neuronal cytoplasmic inclusions (NCI) were found with moderate frequency in the dentate gyrus granular

Fig. 3 Microscopic appearance of representative lesions. (a) Perivascular and parenchymal deposits of iron-containing pigments in the globus pallidus; Berlin blue stain. (b) Numerous spheroids (arrows) in the subthalamic nuclei; Bodian stain. (c) Marked neuronal loss and gliosis in the frontal cortex; HE. (d) Marked gliosis in the frontal white matter; HE. (e) Marked neuronal loss and gliosis in the substantia nigra; HE. (f) Moderate loss of Purkinje cells with several axonal torpedoes (arrows) in the granular layer of the cerebellum; HE. (g) Many NFTs and neuropil threads in the temporal cortex; Gallyas-Braak stain. (h) Many NFTs and neuropil threads in the temporal cortex; AT-8 immunostaining. (i) Foamy spheroids in the substantia nigra; α-synuclein immunostaining. (j) TDP-43-positive neuronal cytoplasmic inclusions in the dentate gyrus granular cells; TDP-43 immunostaining. (k) TDP-43-positive neuronal cytoplasmic inclusions (arrows) and neuronal dystrophic neurites (arrowheads) in the temporal cortex; TDP-43 immunostaining. (l) TDP-43-positive glial cytoplasmic inclusion in the temporal white matter; TDP-43 immunostaining. Scale bars = (a) 100 μm, (b) 50 μm, (c) 100 μm, (d) 50 μm, (e) 40 μm, (f) 100 μm, (g) 50 μm, (h) 100 μm, (i) 50 μm, (j) 50 μm, (k) 50 μm, (l) 15 μm.

Table 1 Previous cases of autopsied NBIA-1 with NFTs

Author	Sex	Age at death (years)	Age at onset (years)	Disease duration (years)	Brain weight (g)	NFT	LB
Wisniewski *et al.*[17]	F	25	8	17	ND	+	–
	M	13	2	11	ND	+	–
Hartmann *et al.*[18]	F	45	18	27	910	+	–
Eidelberg *et al.*[19]	F	48	42	6	1060	+	+
	F	42	32	10	920	+	–
	F	33	31	2	1135	+	–
Fuse *et al.*[9]	M	38	8	30	600	+	+
Gaytan-Garcia *et al.*[24]	M	26	18	8	960	+	+
Yamamoto *et al.*[20]	M	64	57	7	1050	+	–
Hayashi *et al.*[25]	M	26	10	16	850	+	+
Halliday[22]	F	31	1	30	810	+	–
Wakabayashi *et al.*[13]	M	39	9	30	510	+	+
Saito *et al.*[14]	F	44	9	35	775	+	+
	M	38	8	30	600	+	+
Neumann *et al.*[12]	F	27	21	6	1240	+	+
Grimes *et al.*[23]	F	85	76	9	ND	+	–
Zarranz *et al.*[15]	M	61	55	6	ND	+	+
Present patient	F	49	22	27	460	+	–

–, absent; +, present; LB, Lewy body; ND, not determined; NFT, neurofibrillary tangle.

cells (Fig. 3j). These NCI were found with low frequency in the middle and upper cortical layers of the frontal and temporal cortices (Fig. 3k), with moderate frequency in the striatum and the globus pallidus, and were absent in the thalamus, substantia nigra, and amygdala. Relatively few neuronal dystrophic neurites (DN) were found (Fig. 3k) in the sites where NCI were observed. Moreover, TDP-43-positive glial cytoplasmic inclusions (GCI) were found with moderate frequency in the striatum and globus pallidus, and found with low frequency in the frontal and temporal lobes (Fig. 3l) and the thalamus. No neuronal intranuclear inclusions (NII) were observed. The distribution of this TDP-43 pathology overlapped with that of tau pathology. However, tau pathology was much more abundant than TDP-43 pathology. Neither tufted astrocytes nor astrocytic plaques were found. No amyloid plaques, globoid cells, or Pick bodies were observed.

Genetic analysis

These studies were approved by the Institutional Review Boards of Osaka University Hospital and the Minami-Okayama Medical Center, and performed after obtaining written informed consent from the patient's family. Genomic DNA was isolated from the subject's frozen brain tissue using Dr GenTLE (Takara Bio, Otsu, Shiga, Japan) according to the manufacturer's instructions. The entire coding region, exon1C to 7 and surrounding exon-intron boundaries of the pantothenate kinase 2 (*PANK2*) gene were amplified and analyzed by PCR.[4] The amplified products were purified and directly sequenced in both the forward and the reverse directions by Dye Terminator

Cycle Sequencing Ready Reaction (ABI 310 Genetic Analyzer, Perkin-Elmer Biosystems, Foster City, CA, USA) and compared with control DNA. Information concerning the sequence of the PKAN genome was obtained from the website of GenBank accession number BK000010.[4]

No mutations were demonstrated in the *PANK2* gene. However, we found a homozygous polymorphism in the gene: the homozygous c.47G->C substitution resulted in p.G16A in exon 1C.

Survey of the literature

Eighteen NBIA-1 patients with NFT were included in this analysis: one was our original case, 17 were obtained by reviewing the literature[9,12–15,17–20,22–25] and confirming the detailed clinical and pathological findings. We first evaluated the age at onset, age at death and disease duration (Table 1). The ages at onset were 1 to 76 years, the ages at death were 13 to 85 years, and the durations were 2 to 35 years. These NBIA-1 patients appeared to comprise two different groups: one had NFT expression but no LB (NFT-type) and the other had both NFT and LB expressions (NFT/LB-type). The Mann-Whitney U-test was used for statistical comparison of the age at onset, age at death, and disease duration between the NFT type and the NFT/LB type. Fisher's exact probability test was used for comparison of the male-to-female ratio. P-values under 5% were accepted as statistically significant. These statistical analyses were performed using SPSS software version 13.0 for Windows (SPSS Inc., Chicago, IL, US).

There were no differences between the two groups in sex ratio (NFT-type; M/F 2/7, NFT/LB-type; M/F 6/3,

$P = 0.153$), age at onset (NFT-type; 27.4 ± 23.8 years, NFT/LB-type; 20.0 ± 16.1 years, $P = 0.658$), age at death (NFT-type; 43.0 ± 20.3 years, NFT/LB-type; 38.6 ± 10.9 years, $P = 0.691$), disease duration (NFT-type; 15.6 ± 9.6 years, NFT/LB-type; 18.6 ± 11.8 years, $P = 0.722$), and brain weight (NFT-type; 880.8 ± 215.1 g, NFT/LB-type; 824.4 ± 237.0 g, $P = 0.698$).

DISCUSSION

In most cases, the onset of NBIA-1 occurs in the first or second decade and death usually occurs before the age of 30 years. Recent studies suggest that NBIA-1 can develop at any age, and that the phenotype should be extended to include late onset parkinsonism.[32] In the present patient, the initial neurological manifestations were akinesia, resting tremor, and rigidospastic gait at the age of 22. These were later accompanied by progressive dementia, spastic tetraparesis, and myoclonic movements.

The pathological findings in the present case included numerous axonal spheroids and abundant iron deposition with severe neuronal loss and gliosis in the globus pallidus and substantia nigra pars reticulata. We therefore classified our patient as having adult-onset NBIA-1 without known *PANK2* mutations. We confirmed that the substitution in our case was unrelated to the onset of PKAN, and concluded this homozygous polymorphism to be of no significance. The other major pathological characteristics of our patient were the presence of innumerable NFTs and diffuse TDP-43-positive inclusions.

To our knowledge, this is the first report to demonstrate TDP-43 pathology in a NBIA-1 case. The neuronal subcellular localization of TDP-43-positive inclusions is diverse, and TDP-43-positive inclusions consist of neuronal cytoplasmic inclusions (NCI), neuronal dystrophic neurites (DN), and neuronal intranuclear inclusions (NII). Based on the morphology of ubiquitin- or TDP-43-positive inclusions, at least four subtypes were proposed for FTLD-U:[26,33-35] subtype 1 with DNs but few NCIs and no NIIs, subtype 2 with NCIs but few or no DNs and no NIIs, subtype 3 with NCIs and DNs with NIIs, and subtype 4 with NIIs and DNs but few NCIs.[36] Subtype 3 includes cases with *progranulin (PGRN)* mutations and others, and subtype 4 consists of cases with *valosin-containing protein (VCP)* mutations. The morphology of TDP-43-positive inclusions in our NBIA-1 case appears to correspond to that in FTLD-U subtype 2.

Recent reports have revealed various degrees of coexistence of TDP-43 immunoreactivity in a variety of neurodegenerative disorders, including AD, DLB, CBD, Guamanian ALS/PDC, and Huntington's disease.[27-30,37-39] In 2007, Higashi *et al.* investigated TDP-43 pathology in seven FTLD-U cases, 15 AD cases, and 11 DLB cases, and

they found that the amygdalas and hippocampi that were vulnerable to tau or α-synuclein pathology demonstrated more severe TDP-43 pathology in AD and DLB cases than in FTLD-U cases. In contrast, while the frontal cortex and basal ganglia were vulnerable to TDP-43 pathology in FTLD-U, TDP-43 pathology was not observed there in AD and DLB cases. Thus, they suggested that FTLD-U may have a pathogenic mechanism leading to TDP-43 aggregation that is different from AD or DLB.[38] In our NBIA-1 case, severe TDP-43 pathology was widespread in not only the hippocampus but also the frontal and temporal lobes and basal ganglia, and almost absent in the amygdala. This neuroanatomical distribution of TDP-43-positive NCIs was obviously more similar to that in FTLD-U rather than in AD and DLB. In addition, Nakashima-Yasuda *et al.* reported that TDP-43 pathology was detected in the hippocampus and entorhinal cortex from a subset of DLB + AD (31.3%) but not pure DLB cases. These findings might suggest that AD rather than LB pathology is the more dominant risk factor for TDP-43 proteinopathy, as they speculated.[27] The pathological findings of our case, in which tau and TDP-43 pathology were exceedingly more abundant than α-synuclein pathology, are consistent with their speculation.

Clinical and pathological findings for previously described NBIA-1 patients with neurofibrillary pathology are summarized in Table 1. These patients ranged in age from 13 to 85 years (mean 40.8 years) at the time of death, with an average duration of illness of 17.1 years. Clinically, they revealed a slowly progressive or relatively abrupt cognitive decline. Pathologically, NFTs of several cases were widely distributed throughout the cerebral cortex and subcortical nuclei,[9,13-15,18,19,22,24,25] whereas others were relatively confined to the brainstem or hippocampus.[12,20,23] Thus, the distribution patterns of NFTs are diverse. Furthermore, they appear to comprise two different groups, that is, a NFT type and a NFT/LB type. However, the statistical analyses in our study showed no significant differences between the two groups in sex ratio, age at onset, age at death, disease duration, and brain weight. These findings could suggest that this pathological phenotypic difference is not due to an acquired factor. The coexistence of NFTs and LBs (NFT/LB-type) has been reported in only nine patients with NBIA-1.[9,12-15,19,24,25] In one of these nine cases, axonal spheroids were restricted to the globus pallidus, substantia nigra, and gracile and cuneate nuclei.[19] In the other eight patients, numerous spheroids were widely distributed throughout the central nervous system. Based on the above findings, it is likely that the wider the distribution of spheroids, the more extensive the occurrence of LBs in patients with NBIA-1 with LBs.[13] In our case, the abundant axonal spheroids in the subthalamic nucleus and dentate nucleus were also consistently

negative for α-synuclein. Similar negative findings were also reported by Wakabayashi *et al.*,[13] Saito *et al.*,[14] and Zarranz *et al.*[15] This negative finding is inconsistent with the observations made by several authors who have found that the axonal spheroids in NBIA-1 are strongly positive for α-synuclein antibodies.[10,12] Thus, NBIA-1 has various pathological phenotypes according to tau or α-synuclein pathology.

On the other hand, previously reported postmortem examinations consistently present the coexistence of two main histological hallmarks, namely, axonal spheroids and excessive brain iron accumulation. Some authors have favored the view that axonal spheroids are the primary pathological process,[7,40] leading to the classification of NBIA-1 within the spectrum of the diffuse axonal degenerations (Seilterberger disease). Other authors have emphasized that brain iron accumulation is not merely a histological hallmark of NBIA-1 but the first pathogenic abnormality.[8,41,42] In 2001, Koeppen *et al.* reported that double-labeling of ferritin, as an indirect marker of intracellular iron, and phosphorylated neurofilament protein, revealed the close proximity of ferritin-reactive microglial and oligodendroglial processes to tightly packed axons. It was proposed that a primary axonal disorder allows the seepage of iron into the axoplasm, although iron may also contribute to axonal damage.[43] Futhermore, in 2003, Hayflick *et al.* revealed 54 *PANK2* mutations among 123 patients from 98 families with NBIA-1.[41] Pantothenase kinase is a rate-determining enzyme in coenzyme A biosynthesis. It can also lead to a concentration of cysteine in the basal ganglia, and then to an accumulation of iron in these areas.[5]

Based on the above neuropathological perspective, the evidence favors the view that iron accumulation is the first step in the pathological process of NBIA-1. In our review, NBIA-1 has various pathological phenotypes according to tau or α-synuclein pathology. These findings support the possibility that they are a nonspecific cytoskeletal abnormality in NBIA-1, and should not be taken as the basis for its nosological classification. However, further clinicopathological and genetic studies of similar cases will be necessary to characterize this disease entity fully and determine its etiopathology.

ACKNOWLEDGEMENTS

REFERENCES

1. Taylor TD, Litt M, Kramer P *et al.* Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13. *Nat Genet* 1996; **14**: 479–481.

2. Jellinger KA, Dura J. Neurodegeneration with brain iron accumulation, type 1 (Hallervorden-Spatz disease). In: Dickson D, ed. *Pathology & Genetics: Neurodegenerative Diseases*. Basel: ISN Neuropath Press, 2003; 394–399.

3. Arawaka S, Saito Y, Murayama S, Mori H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. *Neurology* 1998; **51**: 887–889.

4. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. *Nat Genet* 2001; **28**: 345–349.

5. Gordon N. Pantothenate kinase-associated neurodegeneration (Hallervorden-Spatz syndrome). *Eur J Paediatr Neurol* 2002; **6**: 243–247.

6. Dooling EC, Schoene WC, Richardson EP Jr. Hallervorden-Spatz syndrome. *Arch Neurol* 1974; **30**: 70–83.

7. Jellinger K. Neuroaxonal dystrophy: its natural history and related disorders. In: Zimmerman H, ed. *Progress in Neuropathology*, Vol. 2. New York: Grune and Stratton, 1973; 129–180.

8. Park BE, Netsky MG, Betsill WL Jr. Pathogenesis of pigment and spheroid formation in Hallervorden-Spatz syndrome and related disorders. *Neurology* 1975; **25**: 1172–1178.

9. Fuse S, Inoue K, Iwata M, Mannen T, Toyokura Y. An autopsy case of Hallervorden-Spatz disease with protracted course of about 30 years (in Japanese with English abstract). *Neurol Med (Tokyo)* 1987; **27**: 155–167.

10. Newell KL, Boyer P, Gomez-Tortosa E *et al.* Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonaldystrophy and acute traumatic brain injury. *J Neuropathol Exp Neurol* 1999; **58**: 1263–1268.

11. Wakabayashi K, Yoshimoto M, Fukushima T *et al.* Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. *Neuropathol Appl Neurobiol* 1999; **25**: 363–368.

12. Neumann M, Adler S, Schluter O, Kremmer E, Benecke R, Kretzschmar HA. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread

cortical and brainstem-type Lewy bodies. *Acta Neuropathol (Berl)* 2000; **100**: 568–574.

13. Wakabayashi K, Fukushima T, Koide R *et al.* Juvenile-onset generalized neuroaxonal dystrophy (Hallervorden-Spatz disease) with diffuse neurofibrillary and lewy body pathology. *Acta Neuropathol (Berl)* 2000; **99**: 331–336.

14. Saito Y, Kawai M, Inoue K *et al.* Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. *J Neurol Sci* 2000; **177**: 48–59.

15. Zarranz JJ, Gómez-Esteban JC, Atarés B, Lezcano E, Forcadas M. Tau-predominant-associated pathology in a sporadic late-onset Hallervorden-Spatz syndrome. *Mov Disord* 2006; **21**: 107–111.

16. Tu PH, Galvin JE, Baba M *et al.* Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. *Ann Neurol* 1998; **44**: 415–422.

17. Wisniewski K, Jervis GA, Moretz RC, Wisniewski HM. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. *Ann Neurol* 1979; **5**: 288–294.

18. Hartmann HA, White SK, Levine RL. Neuroaxonal dystrophy with neuromelanin deposition, neurofibrillary tangles, and neuronal loss: light- and electron-microscopic changes in a 45-year-old woman with progressive psychomotor deterioration. *Acta Neuropathol (Berl)* 1983; **61**: 169–172.

19. Eidelberg D, Sotrel A, Joachim C *et al.* Adult onset Hallervorden-Spatz disease with neurofibrillary pathology: a discrete clinicopathological entity. *Brain* 1987; **110**: 993–1013.

20. Yamamoto T, Kawamura J, Hashimoto S *et al.* Pallido-nigro-luysian atrophy, progressive supranuclear palsy and adult onset Hallervorden-Spatz disease: a case of akinesia as a predominant feature of Parkinsonism. *J Neurol Sci* 1991; **101**: 98–106.

21. Takada K. Early occurrence of Alzheimer's neurofibrillary tangles (NFT) in developmental brain damage and chronic brain diseases with early childhood onset. *Neuropathology* 1993; **13**: 333–335.

22. Halliday W. The nosology of Hallervorden-spatz disease. *J Neurol Sci* 1995; **134** (Suppl): 84–91.

23. Grimes DA, Lang AE, Bergeron C. Late adult onset chorea with typical pathology of Hallervorden-Spatz syndrome. *J Neurol Neurosurg Psychiatry* 2000; **69**: 392–395.

24. Gaytan-Garcia S, Kaufmann JC, Young GB. Adult onset Hallervorden-Spatz syndrome or Seitelberger's disease with late onset: variants of the same entity? A clinico-pathological study. *Clin Neuropathol* 1990; **9**: 136–142.

25. Hayashi S, Akasaki Y, Morimura Y, Takauchi S, Sato M, Miyoshi K. An autopsy case of late infantile and juvenile neuroaxonal dystrophy with diffuse Lewy bodies and neurofibrillary tangles. *Clin Neuropathol* 1992; **11**: 1–5.

26. Neumann M, Sampathu DM, Kwong LK *et al.* Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* 2006; **314**: 130–133.

27. Nakashima-Yasuda H, Uryu K, Robinson J *et al.* Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. *Acta Neuropathol* 2007; **114**: 221–229.

28. Geser F, Winton MJ, Kwong LK *et al.* Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. *Acta Neuropathol* 2008; **115**: 133–145.

29. Hasegawa M, Arai T, Akiyama H *et al.* TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. *Brain* 2007; **130**: 1386–1394.

30. Uryu K, Nakashima-Yasuda H, Forman MS *et al.* Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. *J Neuropathol Exp Neurol* 2008; **67**: 555–564.

31. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. *Neuropathology* 2009; **29**: 566–573.

32. Racette BA, Perry A, D'Avossa G, Perlmutter JS. Late-onset neurodegeneration with brain iron accumulation type 1: expanding the clinical spectrum. *Mov Disord* 2001; **16**: 1148–1152.

33. Forman MS, Mackenzie IR, Cairns NJ *et al.* Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. *J Neuropathol Exp Neurol* 2006; **65**: 571–581.

34. Mackenzie IR, Baborie A, Pickering-Brown S *et al.* Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. *Acta Neuropathol (Berl)* 2006; **112**: 539–549.

35. Sampathu DM, Neumann M, Kwong LK *et al.* Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. *Am J Pathol* 2006; **169**: 1343–1352.

36. Cairns NJ, Bigio EH, Mackenzie IR *et al.* Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathol (Berl)* 2007; **114**: 5–22.

37. Amador-Ortiz C, Lin WL, Ahmed Z *et al*. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. *Ann Neurol* 2007; **61**: 435–445.

38. Higashi S, Iseki E, Yamamoto R *et al*. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. *Brain Res* 2007; **1184**: 284–294.

39. Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of TDP-43 and huntingtin in inclusions of Huntington's disease. *J Neuropathol Exp Neurol* 2008; **67**: 1159–1165.

40. Rozdilsky B, Bolton CF, Takeda M. Neuroaxonal dystrophy: a case of delayed onset and protracted course. *Acta Neuropathol (Berl)* 1971; **17**: 331–340.

41. Hayflick SJ, Westaway SK, Levinson B *et al*. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. *N Engl J Med* 2003; **348**: 33–40.

42. Thomas M, Hayflick SJ, Jankovic J. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. *Mov Disord* 2004; **19**: 36–42.

43. Koeppen AH, Dickson AC. Iron in the Hallervorden-Spatz syndrome. *Pediatr Neurol* 2001; **25**: 148–155.

Usefulness of pharmacist-assisted screening and psychiatric referral program for outpatients with cancer undergoing chemotherapy

Tatsuhiko Ito[1], Ken Shimizu[2,3], Yasuhiko Ichida[4], Yuki Ishibashi[2], Nobuya Akizuki[5], Asao Ogawa[3,6], Maiko Fujimori[3], Naoko Kaneko[7], Ikuyo Ueda[4], Kazuhiko Nakayama[1] and Yosuke Uchitomi[3,6]*

[1]Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan
[2]Psycho-Oncology Division, National Cancer Center Hospital, Tokyo, Japan
[3]Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
[4]Pharmacy Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
[5]Psycho-Oncology Division, Chiba Cancer Center, Chiba-city, Chiba, Japan
[6]Psycho-Oncology Division, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
[7]Tokyo Health Medical Care Public Corporation East Hospital Foundation, Tokyo, Japan

*Correspondence to: Psycho-Oncology Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. E-mail: uchitomi@md.okayama-u.ac.jp

Abstract

Objective: Major depressive disorder (MDD) and adjustment disorder (AD) are common psychiatric disorders in cancer patients but are often overlooked in clinical oncology settings. We introduced a clinical screening program utilizing the Distress and Impact Thermometer (DIT) to identify MDD and AD in cancer outpatients receiving chemotherapy. This study assessed the usefulness of the screening program.

Methods: Pharmacists administered the DIT to consecutive patients undergoing chemotherapy at an outpatient clinic. Psychiatric treatment was recommended to all the patients with positive screening results. The proportion of patients referred to the Psychiatric Service during the program period was then compared with that during a usual care period.

Results: Of the 520 patients who started chemotherapy during the 6-month program period, 5.0% (26/520) were referred to the Psychiatric Service and 2.7% (15/520) were diagnosed as having MDD or AD. No statistically significant difference in the referral rates was observed between the two periods (2.7 vs 1.0%, $p = 0.46$). However, the period from the first chemotherapy treatment until the visit to the Psychiatric Service was significantly shorter during the program period than during the period of usual care (12.9 ± 13.2 days vs 55.6 ± 17.6 days, $p < 0.001$).

Conclusions: The proportion of patients referred to the Psychiatric Service for the treatment of MDD or AD during the program period was not different from that during the usual care period. However, the program was useful for introducing psychiatric treatment at an earlier stage. Further modifications to the program to improve the referral rate are necessary. Copyright © 2011 John Wiley & Sons, Ltd.

Keywords: cancer; oncology; major depressive disorder; adjustment disorder; chemotherapy; outpatients

Introduction

Major depressive disorder (MDD) and adjustment disorder (AD) are the most distressing and prevalent psychiatric disorders in patients with cancer [1]. The prevalence of MDD in patients with cancer has been reported to be 3–7%, while that of AD has been reported to be 4–35% [2–7]. Several studies have indicated that MDD and AD have a serious negative impact on the quality of life of patients [8] and are related to severe suffering, poor adherence to treatment recommendations [9], requests for early death or euthanasia [10–13],

suicidal ideation [14], suicide [15] and the psychological distress of family members [16,17].

Evaluating the psychological distress of cancer patients is extremely difficult for oncology medical staff, and psychological distress is often under-recognized in clinical oncology settings [18–20]. Once recognized, it is often too late to introduce pharmacotherapy to improve the depressive symptoms of advanced cancer patients [21]. As psychotherapy [22] and pharmacotherapy [23] are known to be effective means of treating these disorders, a screening strategy to enable early detection and treatment for depression in cancer patients

seems like a reasonable step in treating this condition.

Previous studies have confirmed the efficacy of psychological screening strategies for depression in primary-care settings, with programs combining psychological screening with referrals to mental health specialists appearing to be the most powerful intervention [24,25]. In oncology settings, although less empirical evidence is available than for primary-care settings, cancer patients are known to have a high risk of depressive disorders (mainly MDD and ADs according to the Diagnosis and Statistical Manual IV (DSM-IV) criteria) [2–7]. Psychological screening can detect depressive disorders in cancer patients [26], and psychological interventions can alleviate the depressive disorders that are detected by psychological screening [27–29]. Together, this evidence suggests the efficacy of psychological screening for cancer patients, and guidelines such as those published by the National Comprehensive Cancer Network [30] and the National Institute for Health and Clinical Excellence have been recommended as clinically feasible practices for combining screening with interventions from mental health specialists for the treatment of psychological distress in cancer patients.

We previously examined the usefulness of psychological screening for cancer patients using the Distress and Impact Thermometer (DIT) [31]. Furthermore, we have developed and introduced a Nurse-Assisted Screening and Psychiatric Referral Program (NASPRP) for inpatients [26].

With the recent introduction of chemotherapy being performed in outpatient clinics, the amount of time that physicians and medical staffs spend with their outpatients has been drastically reduced compared with inpatients [32]. Thus, we must modify the NASPRP for use in outpatient clinics.

We have planned two types of screening program for ambulatory patients. One program, reported in the present study, targets patients undergoing chemotherapy by cooperating with pharmacists. The other program, which was reported in a previous article [33], is a general outpatient model involving a collaboration among nurses, primary oncologists, and Psychiatric Services.

The primary aim of the current study was to examine preliminarily the usefulness of our screening program modified for outpatients with cancer who are undergoing chemotherapy. We hypothesized that the use of this screening program in outpatient clinics would result in a higher rate of the referral of cancer patients to the Psychiatric Service and earlier psychiatric referral for the treatment of major depressive and ADs. The secondary aim was to evaluate the feasibility of administering the DIT in an outpatient clinic setting.

Materials and methods

Modification of the screening program for use in an outpatient clinic setting

First, we modified the NASPRP to suit an outpatient clinic setting. As the utility of the NASPRP was limited by the amount of time required for nurses to administer the DIT, the NASPRP was adjusted as explained below. First, pharmacists were asked to administer the screening program. Pharmacists routinely explain the effects and adverse effects of first or new chemotherapy regimens to cancer patients undergoing chemotherapy in an outpatient setting. Therefore, pharmacists are in close communication with cancer patients. Second, to shorten the explanation time, we prepared a brief pamphlet introducing the Psychiatric Service and screening program; a detailed pamphlet describing the self-management of mental health was also prepared.

Before implementing the screening program, all the pharmacists attended a 2-hour lecture given by a trained psychiatrist regarding the epidemiology, impact, risk factors, under-recognition, and appropriate management of psychiatric disorders in cancer patients. Additionally, the pharmacists underwent role-play training to learn how to implement the DIT and to give recommendations for psychiatric referral.

Distress and impact thermometer

The DIT uses a two-item, self-administered rating scale. Our group developed the DIT by adding the Impact Thermometer to the Distress Thermometer [31,34,35]. Each 'distress' and 'impact' question is scored using an 11-point Likert scale, with scores ranging from 0 to 10 and a high score indicating an unfavorable status.

Screening program procedure

The screening program was implemented between April and September 2007, at the outpatient treatment center of the National Cancer Center Hospital East (NCCH-E). Consecutive cancer patients beginning chemotherapy at the outpatient treatment center of the NCCH-E during this period were enrolled. Pharmacists routinely provide instructions regarding new chemotherapy regimens to patients beginning chemotherapy; on such occasions, the pharmacists also provided information regarding the Psychiatric Service using a brief pamphlet and invited the patients to complete the DIT. The pharmacist then completed the screening program sheet, which is a record of the patient's DIT scores, age, sex, cancer site, cancer stage, and Eastern Cooperative Oncology Group (ECOG) performance status. The screening questionnaires

were administered again during the second visit of each patient beginning a new chemotherapy regimen. If a patient scored equal to or more than each cut-off point ($\geq$4 for distress and $\geq$3 for impact) the screening result was regarded as positive.

The pharmacist in charge recommended a consultation with the Psychiatric Service to all the patients with a positive screening result. If a patient accepted the recommendation, the patient visited the Psychiatric Service and was examined by trained psychiatrists using a clinical diagnostic interview based on the DSM-IV (published by the American Psychological Association) criteria. If a DIT-positive patient refused a consultation, the pharmacist gave them a detailed pamphlet regarding the self-management of mental health. However, if the patient was suspected of having severe psychological distress, the pharmacist discussed the case with the psychiatrists and monitored the patient carefully under their supervision. In addition, the pharmacist provided a brief feedback on the patient's medical chart regarding the screening results.

During the screening program, the pharmacists and psychiatrists held monthly meetings to discuss any issue that emerged.

Data collection

Clinical data were extracted from the patients' medical charts and the computerized database of the electronic medical record at NCCH-E.

Measures

The usefulness of the screening program was evaluated by calculating the proportion of patients referred to the Psychiatric Service and treated for major depressive or AD among all the outpatients who had begun a new chemotherapy regimen within 3 months of their visit to the outpatient clinic. The number of days from the first chemotherapy treatment to the first visit to the Psychiatric Service was examined as an indicator of early detection and the early introduction of treatment. The number of patients referred to psychiatrists and the number of days from the first chemotherapy treatment to the first visit to the Psychiatric Service were confirmed using the computerized database of the electronic medical record at NCCH-E, which provides a definitive record of the dates of chemotherapy and psychiatry consultation. The feasibility of the DIT in a clinical oncology outpatient setting was evaluated by calculating the proportion of patients that underwent screening, which was the portion of patients who completed the DIT on their first or second visit to the outpatient clinic among all the outpatients who began a new chemotherapy regimen.

Sample size estimation

We estimated that the psychiatric referral rate (%) for the treatment of major depressive and ADs in patients with cancer was 1% during a usual care period (January 2005–December 2005) and that a 5% improvement after the implementation of the screening program would be reasonable. At a 5% significance level (two-sided Student t-test) and a 80% power, a sample size of 332 patients was needed for each period. In our hospital, approximately 70 patients began receiving chemotherapy at the outpatient treatment center every month. Thus, we concluded that a 6-month study period would be adequate for both the screening program and the period of usual care.

Patients treated during the screening program

All consecutive cancer patients who began chemotherapy at the outpatient treatment center of NCCH-E in Japan between April 1 and September 30, 2007 (program-period) were included in the screening program.

Patients during the usual care

All consecutive cancer patients who began chemotherapy at the outpatient treatment center of NCCH-E between April 1 and September 30, 2006 (usual care-period) received usual care.

Analysis

The current study was conducted using a retrospective cohort analysis comparing patients treated during the program-period with historical control data gathered during the usual care-period. The characteristics (age, sex, and cancer site) of the patients treated during the program-period and those treated during the usual care-period were compared using a chi-square test. The usefulness of the screening program was evaluated by comparing the proportion of patients referred to the Psychiatric Service for major depressive or AD during the program-period and the usual care-period using a chi-square test. As an index for early treatment introduction, we compared the number of days from the first chemotherapy treatment until the first visit to the Psychiatric Service for the treatment of major depressive or AD during the program-period and the usual care-period using a Student t-test. All tests were two-tailed. All analyses were performed using SPSS 14.0 J for Windows statistical software (SPSS Japan Institute, Tokyo, Japan).

The administration of the DIT and the recommendations for psychiatric referral were performed based on clinical need, and all other data were obtained as part of routine clinical assessments.

Therefore, the present study required very little deviation from standard clinical practice. As this study was a retrospective review of the program-period and the usual care-period for the purpose of comparing two types of clinical practices, the written consent of the patients was not obtained.

The medical record data used in this study were collected and analyzed after approval from the Institutional Review Board of the National Cancer Center, Japan. All data were de-identified and analyzed in aggregate form.

Results

Patient characteristics

During the program-period, 520 patients began receiving chemotherapy in an outpatient setting at the NCCH-E; 478 patients started receiving chemotherapy in an outpatient setting during the usual care-period. As shown in Table 1, the age, sex, and cancer sites of the patients treated during each period were comparable.

Usefulness of the screening program

Of the 478 patients who started chemotherapy during the usual care-period, 9 patients were referred to the Psychiatric Service; the referral rate was 1.9% (9/478). Of the nine patients that were referred, five patients were diagnosed as having

MDD ($n = 3$) or ADs ($n = 2$) and began receiving treatment for these conditions. Two of the other four patients did not fulfill the DSM-IV diagnostic criteria for any psychiatric disorder, and the other two patients were diagnosed as having akathisia and sleep disorder, respectively. Thus, the proportion of patients referred for major depressive or ADs was 1.0% (5/478). The number of days from the first chemotherapy treatment to the first visit to the Psychiatric Service for the treatment of major depressive or AD was 55.6 days (SD = 17.6 days).

Figure 1 shows the process of the screening program. Of the 520 patients who started chemotherapy during the program-period, 26 patients were referred to the Psychiatric Service and were examined by psychiatrists; the referral rate was 5.0% (26/520). Of the 26 patients that were referred, 15 patients were diagnosed as having MDD ($n = 2$) or ADs ($n = 13$) and began receiving treatment for these conditions. Nine of the other eleven patients did not fulfill the DSM-IV diagnostic criteria for any psychiatric disorder, and the other two patients were diagnosed with delirium and sleep disorder, respectively. Thus, the proportion of patients referred for major depressive or ADs was 2.7% (15/520). The number of days from the first chemotherapy treatment to the first visit to the Psychiatric Service for the treatment of major depressive or AD was 12.9 days (SD = 13.2 days).

The proportion of patients referred to the Psychiatric Service and treated for a major

Table 1. Characteristics of outpatients who received chemotherapy between April 1, 2007 and September 30, 2007 (program-period: n = 520) or April 1, 2006 and September 30, 2006 (usual care-period; n = 478) at NCCH-E

|	No. of patients (%)		
	During program-period	During usual care-period	p-Value
Total patients	520 (100)	478 (100)	
Age (mean±SD)	61.4±10.8	62.8±10.9	0.66
Male (%)	281 (54.0)	271 (56.7)	0.40
Primary cancer site			0.18
Lung	114 (21.9)	86 (18.0)	
Colon, rectum	111 (21.4)	71 (14.9)	
Breast	82 (15.8)	56 (11.7)	
Hematopoietic and lymphatic tissue	56 (10.8)	72 (15.1)	
Stomach	39 (7.5)	40 (8.4)	
Pancreas	39 (7.5)	63 (13.2)	
Esophagus	24 (4.6)	31 (6.1)	
Liver, bile duct, gall bladder	16 (3.0)	30 (6.3)	
Head and neck	15 (2.9)	13 (2.7)	
Other	24 (4.6)	16 (3.3)	
Stage			
IV or recurrent	349 (67.1)		
III	108 (20.8)		
II	50 (9.6)		
I	13 (2.5)		
Performance status (ECOG)			
0	370 (71.1)		
1	136 (26.2)		
2	13 (2.5)		
3	1 (0.2)		
4	0 (0)		

Figure 1. Number of patients screened and referred

depressive or AD was not significantly different between the two periods (2.7% during the program-period vs 1.0% during the usual care-period, $p = 0.46$). However, the number of days from the first chemotherapy treatment until the first visit to the Psychiatric Service was significantly shorter during the program-period than during the usual care-period (12.9 ± 13.2 days vs 55.6 ± 17.6 days, respectively; $p < 0.001$). In addition, the proportion of patients referred to the Psychiatric Service that did not fulfill the DSM-IV diagnostic criteria for any psychiatric disorder was not significantly different between the two periods (1.7% during the program-period vs 0.6% during the usual care-period, $p = 0.12$).

Feasibility of the screening program

During the program-period, 396 patients completed the DIT during their first visit to the outpatient clinic; thus, 76.2% of the patients participated in the screening. Of the 396 patients who were screened during their first visit to the outpatient clinic, the screening results were positive in 118 patients, yielding a positive screening rate of 29.8%. The mean levels of the distress and impact scores on the DIT were 3.5 (SD = 2.8) and 2.2 (SD = 2.5), respectively. Of the 520 patients treated during the program-period, 408 patients made a second visit to the outpatient clinic for chemotherapy. Of these 408 patients, 298 patients completed the DIT; thus, 71.8% of the patients participated in the screening. Of the 298 patients who were screened during their second visit to the outpatient clinic, the screening results were positive in 64 patients, yielding a positive screening rate of

21.8%. The mean levels of the distress and impact scores on the DIT were 2.4 (SD = 2.4) and 1.9 (SD = 2.3), respectively. Five to ten minutes were required for the pharmacists to provide information about the Psychiatric Service, invite the patient to complete the DIT, and recommend a consultation with the Psychiatric Service.

Discussion

This preliminary study examined the usefulness and feasibility of a modified psychological screening and intervention program administered by pharmacists to cancer patients receiving chemotherapy in an outpatient clinic. Unexpectedly, the proportion of patients referred to the Psychiatric Service and treated for major depressive or ADs was not significantly different between the program-period and the usual care-period. However, the number of days between the first chemotherapy treatment and the first visit to the Psychiatric Service for the treatment of a major depressive or AD was significantly shorter during the program-period than during the usual care-period.

A potential harm of the screening intervention is false-positive patients reaching the Psychiatric Service. However, the proportion of patients referred to the Psychiatric Service that did not fulfill the DSM-IV diagnostic criteria for any psychiatric disorder was not significantly different between the two periods.

We previously reported that our original program for screening cancer inpatients (NASPRP) achieved a higher referral rate than that obtained during usual care [26], but the presently reported

modified screening program for outpatients did not. One reason for this difference might be the study setting. Inpatients must remain in the hospital all day long, and if they accept a psychiatric referral, the psychiatric consultation occurs at their bedside. The presently reported screening program was intended for use in an outpatient clinic setting for patients who do not spend lengthy periods of time within a hospital. To receive psychiatric treatment in an outpatient clinic setting, the patient must quickly move to another room after completing their chemotherapy, and this burden might be a barrier to the acceptance of psychiatric referral. Second, adverse effects of chemotherapy such as fatigue and nausea on the day of treatment might make it difficult for patients to accept a psychiatric referral. Finally, the actual incidence of psychiatric disorders was relatively low, as the positive screening rate in this outpatient program was lower than that obtained using the NASPRP (29.8, 21.8 vs 49.6%).

The 'Distress Screening Program in Ambulatory Care' (DICPAC program) is a general outpatient screening model that has achieved a relatively high referral rate [33]. One difference between the DICPAC program and the presently reported screening program is the target population. The DISPAC program was used almost exclusively for female patients with breast or gynecological cancer. Female patients might be more likely to accept a referral to the Psychiatric Service than male patients [26]. Second, the attending oncologist provided the referrals to the Psychiatric service in the DISPAC program. The recommendations of physicians might have a larger impact on patients than the recommendations of pharmacists, regardless of the index disease [36]. Lastly, similar to the difference between the present screening program and the NASPRP, the positive screening rate obtained using this program was lower than that obtained using the DISPAC program (29.8, 21.8 vs 37.0%).

The positive screening rate was 29.8% at the time of the first visit and 21.8% at the time of the second visit, yet most of the positively screened patients did not accept the referral to the Psychiatric Service. Although we did not assess the prevalence of MDD and ADs in the targeted population, it is very likely that most of the patients with MDD and ADs would remain untreated, even if the screening program was introduced. In addition, patients who refused screening may contain the larger fraction of those in need of the Psychiatric Service. Thus, the presently reported screening program requires further improvement, and further study is needed to optimize the applicability of psychiatric consultations by addressing factors that promote the acceptance of psychiatric referral. Specifically, the communication skills of the pharmacists might

need to be further strengthened. The changes in staff involving mental health screening may have significant effect. And we may need flag for clinicians those who refused screening for further assessment using other tools. In addition, mental health specialists might need to attend the bedsides of patients during their treatment in the outpatient clinic to reduce distance barriers to psychiatric treatment.

An additional but important finding was the feasibility of administering the DIT to outpatients with cancer. The percentages of patients who completed the DIT during their first and second visits to the outpatient clinic were 76.2 and 71.8%, respectively. In our previous report, 86% of the inpatients completed the DIT in a clinical oncology setting. Another study has reported that the Hospital Anxiety and Depression Scale was administered to 70% of oncology patients [37]; thus, the completion rate in the present study was marginally higher. Compared with these previous reports, the current results suggest that the DIT might be useful as a brief screening tool for detecting psychological distress in cancer patients undergo chemotherapy in busy outpatient settings. The reasons why some patients did not complete the DIT in this study are unknown.

This study has several limitations. First, this study was a retrospective analysis that compared available historical data and our experience with clinical intervention. The comparison group was not systematically controlled to ensure comparability, and some bias in patient selection might have occurred. Second, the results of this study must be considered provisional, as this study was performed at a single cancer center hospital. Our group must be careful in generalizing these results to other oncology settings. Third, although we made the clinical diagnoses according to the DSM-IV criteria, this method is less robust than a structured diagnostic interview. Some possibility of assessment bias also exists, since the four psychiatrists who diagnosed the referred patients were associated with this study. Furthermore, we were unable to assess the interrater reliability of the DSM-IV diagnosis. Fourth, although the screening program resulted in the earlier introduction of treatment for major depressive and ADs in outpatients with cancer, this result is a surrogate endpoint, and its clinical significance remains unclear. Further demonstration that these processes result in a better patient outcome, such as an improvement in the patients' quality of life or the successful treatment of major depressive and ADs, is needed.

In conclusion, a clinical screening program administered by pharmacists that uses the DIT to identify major depressive and ADs in cancer outpatients receiving chemotherapy and introduces them to psychiatric treatment was feasible and

useful for the early introduction of treatment, but the proportion of patients referred for the treatment of major depressive or ADs was not different from that obtained during usual care. Thus, further modification of the present program to overcome barriers to introducing patients with positive screening results to the Psychiatric Service, resulting in the alleviation of psychological distress and a better quality of life, is needed.

Acknowledgements

References

1. Derogatis LR. The prevalence of psychiatric disorders among cancer patients. *J Am Med Assoc* 1983;**249**: 751–757.
2. Akechi T, Okuyama T, Imoto S *et al.* Biomedical and psychosocial determinants of psychiatric morbidity among postoperative ambulatory breast cancer patients. *Breast Cancer Res Treat* 2001;**65**:195–202.
3. Akechi T, Nakano T, Okamura H *et al.* Psychiatric disorders in cancer patients: descriptive analysis of 1721 psychiatric referrals at two Japanese cancer center hospitals. *Jpn J Clin Oncol* 2001;**31**:188–194.
4. Akechi T, Okamura H, Nishiwaki Y *et al.* Psychiatric disorders and associated and predictive factors in patients with unresectable non-small cell lung cancer. A longitudinal study. *Cancer* 2001;**92**:2609–2622.
5. Kugaya A, Akechi T *et al.* Prevalence, predictive factors, and screening of psychological distress in patients with newly diagnosed head and neck cancer. *Cancer* 2000;**88**:2817–2823.
6. Okamura H, Akechi T *et al.* Psychological distress following first recurrence of disease in patients with breast cancer: prevalence and risk factors. *Breast Cancer Res Treat* 2000;**61**:131–137.
7. Uchitomi Y, Mikami I, Kugaya A *et al.* Depression after successful treatment for non-small cell lung cancer: a 3-month follow-up study. *Cancer* 2000;**89**: 1172–1179.
8. Grassi L, Indelli M, Marzola M *et al.* Depressive symptoms and quality of life in home-care-assisted cancer patients. *J Pain Symptom Manage* 1996;**12**:300.
9. Colleoni M, Mandala M, Peruzzotti G *et al.* Depression and degree of acceptance of adjuvant cytotoxic drugs. *Lancet* 2000;**356**:1326–1327.
10. Breitbart W, Rosenfeld B, Pessin H *et al.* Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. *J Am Med Assoc* 2000;**284**: 2907–2911.
11. Akechi T. Desire for early death in cancer patients and clinical oncology. *Jpn J Clin Oncol* 1999;**29**:646.
12. Akechi T, Kugaya A, Okamura H *et al.* Suicidal thoughts in cancer patients: clinical experience in psycho-oncology. *Psychiatry Clin Neurosci* 1999;**53**: 569–573.
13. Chochinov HM, Wilson KG, Enns M *et al.* Desire for death in the terminally ill. *Am J Psychiatry* 1995;**152**: 1185–1191.
14. Akechi T, Okamura H, Yamawaki S *et al.* Why do some cancer patients with depression desire an early death and others do not? *Psychosomatics* 2001;**42**: 141–145.
15. Harris EC, Barraclough BM. Suicide as an outcome for medical disorders. *Medicine* 1994;**73**:281–296.
16. Cassileth BR, Lusk EJ, Strouse TB, Miller DS, Brown LL, Cross PA. A psychological analysis of cancer patients and their next-of-kin. *Cancer* 1985;**55**: 72–76.
17. Harrison J, Haddad P, Maguire P. The impact of cancer on key relatives: a comparison of relative and patient concerns. *Eur J Cancer* 1995;**31A**:1736–1740.
18. Passik SD, Dugan W, McDonald MV *et al.* Oncologists' recognition of depression in their patients with cancer. *J Clin Oncol* 1998;**16**:1594–1600.
19. McDonald MV, Passik SD, Dugan W *et al.* Nurses' recognition of depression in their patients with cancer. *Oncol Nurs Forum* 1999;**26**:593–599.
20. Sollner W, DeVries A, Steixner E *et al.* How successful are oncologists in identifying patient distress, perceived social support and need for psychosocial counselling? *Br J Cancer* 2001;**84**:179–185.
21. Lloyd-Williams M, Friedman T, Rudd N. A survey of antidepressant prescribing in the terminally ill. *Palliat Med* 1999;**13**:243–248.
22. Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: result of two meta-analyses. *Br J Cancer* 1999; **80**:1770–1780.
23. Gill D, Hatcher S. A systematic review of the treatment of depression with antidepressant drugs in patients who also have a physical illness. *J Psychosom Res* 1999;**47**: 131–143.
24. Gilbody SM, House AO, Sheldon TA. Routinely administered questionnaires for depression and anxiety: systematic review. *Br Med J* 2001;**322**:406–409.
25. Bower P, Gilbody S, Richards D *et al.* Collaborative care for depression in primary care: making sense of a complex intervention: systematic review and meta-regression. *Br J Psychiatry* 2006;**189**:484–493.
26. Shimizu K, Akechi T, Okamura M *et al.* Usefulness of the nurse-assisted screening and psychiatric referral program. *Cancer* 2005;**103**:1949–1956.
27. Kornblith AB, Doewll JM, Herndon JE *et al.* Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. *Cancer* 2006;**107**:2706–2714.
28. Ell K, Xie B, Quon B *et al.* Randomized controlled trial of collaborative care management of depression among low-income. *J Clin Oncol* 2008;**26**:4488–4496.
29. Strong V, Waters R, Hibberd C *et al.* Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. *Lancet* 2008;**372**:40–48.
30. National Comprehensive Cancer Network. Distress management clinical practice guidelines. *J Natl Comp Cancer Netw* 2003;**1**:344–374.
31. Akizuki N, Yamawaki S, Akechi T *et al.* Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. *J Pain Symptom Manage* 2005;**29**: 91–99.
32. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC. Trends in the aggressiveness of cancer care near the end of life. *J Clin Oncol* 2004; **22**:315–321.
33. Shimizu K, Ishibashi Y, Umezawa S *et al.* Feasibility and usefulness of the distress screening program in ambulatory care in clinical oncology practice. *Psycho-Oncology* 2010;**19**:718–725.